Beta-1,3-Galactosyl-O-Glycosyl-Glycoprotein Beta-1,6-N-Acetylglucosaminyltransferase (GCNT1) Antibody
Pida mas información
935106861
info@markelab.com
Precio
250€ (80 µl)
Antibody anti-GCNT1
proveedor
Abbexareference
abx031590Tested Applications
ELISA, WB, IHCreactivity
Humanstatus
RUOclonality
PolyclonalDescripción
Glycosylation is one of the most universal but at the same time complex protein modifications. Modification with sugar moeties can be both co translational and post translational, occurring in the endoplasmatic reticulum and golgi. Three different forms of glycosylation can be distinguished: N-linked oligosaccharides, O-linked oligosaccharides and glycosyl phosphatidylinositol (GPI-) anchors. Glycosylation results in thousands of distinct, bioactive glycoproteins resident throughout the cell that strongly determine protein-protein, carbohydrate-protein, membrane, and adhesion properties. Diseases associated with glycosylation defects include Congenital disorders of glycosylation, (CDG), also known as carbohydrate deficient glycoprotein syndromes, and diseases associated with advanced aging.
Background
Glucosaminyl (N-acetyl) transferase 1 (GCNT1) is a glycosyltransferase that catalyzes the addition of N-acetylglucosamine to mucin-type O-glycans, forming core 2 and core 4 branched structures critical for glycoprotein biosynthesis GCNT1 plays a key role in the synthesis of mucins, which protect epithelial barriers in the gastrointestinal and respiratory tracts by regulating mucus production and cell adhesion It is expressed in various tissues, particularly those with high mucus turnover, and is vital for immune responses and cellular signaling Dysregulation of GCNT1 has been associated with cancer progression, especially in breast and gastrointestinal cancers, where aberrant glycosylation promotes tumor invasion and metastasis Additionally, GCNT1 contributes to inflammatory diseases, impacting immune cell trafficking and epithelial defense pathways Studies highlight its involvement in maintaining epithelial integrity and its therapeutic potential as a target for diseases characterized by disrupted glycosylation patterns
Características del producto
category
Primary Antibodies
clonality
Polyclonal
reactivity
Human
immunogen target
Beta-1,3-Galactosyl-O-Glycosyl-Glycoprotein Beta-1,6-N-Acetylglucosaminyltransferase (GCNT1)
host
Rabbit
conjugation
Unconjugated
form
Liquid
tested applications
ELISA, WB, IHC
purification
Purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
buffer
PBS containing 0.09% sodium azide.
size 1
80 µl
size 2
400 µl
storage
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
or code
GCNT1
dry ice
No
availability
Shipped within 5-10 working days.
alias
G6NT,C2GNT,C2GNT1,NACGT2,NAGCT2,C2GNT-L,C2GlcNAcT
uniprot id
note
This product is for research use only.
Quizá le pueda interesar
Beta-1,3-Galactosyl-O-Glycosyl-Glycoprotein Beta-1,6-N-Acetylglucosaminyltransferase (GCNT1) Antibody
proveedor
Abbexareference
abx029321Tested Applications
ELISA, WBreactivity
Humanstatus
RUOclonality
PolyclonalThis gene is a member of the beta-1, 6-N-acetylglucosaminyltransferase gene family. It is essential to the formation of ...
281.25€ (80 µl)
Ver másBeta-1,3-Galactosyl-O-Glycosyl-Glycoprotein Beta-1,6-N-Acetylglucosaminyltransferase (GCNT1) Antibody
proveedor
Abbexareference
abx031589Tested Applications
ELISA, WB, IHCreactivity
Human, Mousestatus
RUOclonality
PolyclonalGlycosylation is one of the most universal but at the same time complex protein modifications. Modification with sugar m...
281.25€ (80 µl)
Ver másBeta-1,3-Galactosyl-O-Glycosyl-Glycoprotein Beta-1,6-N-Acetylglucosaminyltransferase (GCNT1) Antibody
proveedor
Abbexareference
abx031590Tested Applications
ELISA, WB, IHCreactivity
Humanstatus
RUOclonality
PolyclonalGlycosylation is one of the most universal but at the same time complex protein modifications. Modification with sugar m...
250€ (80 µl)
Ver más